system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Aged, Biocompatible Materials, Cosmetic Techniques, Dermatologic Agents, Durapatite, Female, Follow-Up Studies, Humans, Keloid, Lip, Male, Microspheres, Middle Aged, New York, Nose, Patient Satisfaction, Prospective Studies, Rejuvenation, Risk Assessment, Skin Aging, Skin Pigmentation, Treatment Outcome.
user
Does six-month safety results of calcium hydroxylapatite for treatment of nasolabial fold in Fitzpatrick skin types IV to VI? Context: Recently, the cosmetic market has seen an increase in the options for treatment for people with dark skin. This study evaluates the use of calcium hydroxylapatite (CaHA), a dermal filler indicated for the correction of moderate to severe facial wrinkles and folds, including the nasolabial folds (NLFs) in individuals with dark skin. This open-label, nonrandomized, prospective, five-center trial enrolled 100 patients aged 18 and older with Fitzpatrick skin types IV to VI. CaHA was injected subdermally with a 25- to 27-gauge needle. Participants received a range of 0.6 to 2.8 mL of CaHA and returned at 3 and 6 months to be assessed for keloid formation, hypertrophic scarring, and hyper- or hypopigmentation. If necessary, each subject was offered a touch-up at the conclusion of the 6-month visit. No reports of keloid formation, hypertrophic scarring, hypo- or hyperpigmentation, or other clinically significant adverse events were recorded.
assistant
People with dark skin injected subdermally with CaHA do not show signs of keloid formation, hypertrophic scarring, or hyper- or hypopigmentation. Because of this safety feature, as well as other characteristics of the product already shown in clinical literature, CaHA is an attractive dermal filler in this population. Final Decision: yes